Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies

Background: The folate receptor (FR) is frequently over-expressed on human cancer cells and may be a suitable target for radiopharmaceuticals. Because of FR expression in the kidneys, the rapidly renal clearing folate is not well suited as a carrier for therapeutic radionuclides. As an alternative, folate-immunoglobulin conjugates were studied as potential carriers for radionuclides. Materials and Methods: Two types of conjugate were evaluated: (i) folate conjugated to osteosarcoma antigen directed murine monoclonal antibodies TP-1 and TP-3 or (ii) folate conjugated to non-specific polyclonal human IgG (HIg6). These constructs were labelled with At-211 or I-125. Results: The folate-HIg6-radionuclide conjugate showed high affinity to immobilized folate binding protein and also to folate receptor-expressing cells. Folate conjugates of TP-1 and TP-3 had a selective binding in vitro to antigen-expressing tumor cells and also to cells expressing FR only, thus the folate antibody constructs possessed dual affinity binding. Comparisons between folate-conjugated and non-folated antibody in Balb/C mice showed that the folate did not markedly change the properties of the radiolabelled antibody. Conclusion: It was demonstrated that folate-conjugated antibodies carrying therapeutic radionuclides have relevant properties for the targeting of tumor cells expressing FR.     «

Background: The folate receptor (FR) is frequently over-expressed on human cancer cells and may be a suitable target for radiopharmaceuticals. Because of FR expression in the kidneys, the rapidly renal clearing folate is not well suited as a carrier for therapeutic radionuclides. As an alternative, folate-immunoglobulin conjugates were studied as potential carriers for radionuclides. Materials and Methods: Two types of conjugate were evaluated: (i) folate conjugated to osteosarcoma antigen direc...     »